Delegates at the meeting on International Standards for Oral Cholera Vaccines in Seoul, South Korea. Image Courtesy of the International Vaccine Institute (IVI-Seoul)
During the meeting attendees agreed on the importance of developing reference reagents for coating antigens and primary detection antibodies used in this ELISA as well as a reference vaccine. Delegates highlighted the need for these reagents to be tested by a wide range of laboratories in an international collaborative study.
The proposed reference reagents will be filled and freeze-dried at NIBSC specialist manufacturing facility. Pending financial support, materials should be available within four to five years. The standards will support delivery of oral cholera vaccines for public health campaigns in Low and Middle Income countries and the management of the global WHO stock pile.
Dr Sjoerd Rijpkema, Prinicpal Scientist at NIBSC and one of the organisers of the meeting comments:
“The meeting provided us with vital information on the variety of ELISA formats used for batch release and the needs of both manufacturers and regulatory agencies to support and expedite the batch release of this life saving vaccine.’’
A full report from the meeting is due to be submitted for publication.
Find out more about NIBSC work on Cholera.
"The meeting provided us with vital information on the variety of ELISA formats used for batch release and the needs of both manufacturers and regulatory agencies"
Dr Sjoerd Rijpkema, Prinicpal Scientist at NIBSC